Late-stage ozanimod trials are ongoing in ulcerative ... with Merck KGaA’s Mavenclad (cladribine), which has a difference mechanism of action but was cleared for the same indications by the ...

Regulators in the US and EU have formally started their review of Celgene’s oral drug ozanimod for multiple sclerosis, setting up verdicts next year. The news is a relief to Celgene after its ...

Exposure-adjusted incidence rates for any treatment-emergent adverse events among patients with ulcerative colitis or relapsing multiple sclerosis receiving ozanimod were 81.1 and 65.0 per 100 patient ...